These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 34305891)

  • 21. Six-year outcomes in broadly HLA-sensitized living donor transplant recipients desensitized with intravenous immunoglobulin and rituximab.
    Kahwaji J; Jordan SC; Najjar R; Wongsaroj P; Choi J; Peng A; Villicana R; Vo A
    Transpl Int; 2016 Dec; 29(12):1276-1285. PubMed ID: 27529314
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
    Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
    Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intravenous pulse administration of cyclophosphamide is an effective and safe treatment for sensitized cardiac allograft recipients.
    Itescu S; Burke E; Lietz K; John R; Mancini D; Michler R; Rose E; Oz M; Edwards N
    Circulation; 2002 Mar; 105(10):1214-9. PubMed ID: 11889016
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multicenter evaluation of a national organ sharing policy for highly sensitized patients listed for heart transplantation in Canada.
    Clarke B; Ducharme A; Giannetti N; Kim D; McDonald M; Pflugfelder P; Rajda M; Sénéchal M; Stadnick E; Toma M; Zieroth S; Isaac D
    J Heart Lung Transplant; 2017 May; 36(5):491-498. PubMed ID: 28162932
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of immunoadsorption to reduce donor-specific alloantibodies in kidney-transplant candidates.
    Rostaing L; Congy N; Aarnink A; Maggioni S; Allal A; Sallusto F; Game X; Kamar N
    Exp Clin Transplant; 2015 Apr; 13 Suppl 1():201-6. PubMed ID: 25894155
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Successful kidney transplantation after desensitization using plasmapheresis, low-dose intravenous immunoglobulin, and rituximab in highly sensitized patients: a single-center experience.
    Jin MK; Cho JH; Kwon O; Hong KD; Choi JY; Yoon SH; Park SH; Kim YL; Kim CD
    Transplant Proc; 2012 Jan; 44(1):200-3. PubMed ID: 22310614
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Kidney transplant in highly sensitized patients after desensitization with plasmapheresis and low-dose intravenous immunoglobulin.
    Yuan XP; Wang CX; Gao W; Fu Q; He XS
    Exp Clin Transplant; 2010 Jun; 8(2):130-5. PubMed ID: 20565369
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peri-operative third party red blood cell transfusion in renal transplantation and the risk of antibody-mediated rejection and graft loss.
    Fidler S; Swaminathan R; Lim W; Ferrari P; Witt C; Christiansen FT; D'Orsogna LJ; Irish AB
    Transpl Immunol; 2013 Dec; 29(1-4):22-7. PubMed ID: 24090807
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Desensitization and Prevention of Antibody-Mediated Rejection in Vascularized Composite Allotransplantation by Syngeneic Hematopoietic Stem Cell Transplantation.
    Wang HD; Fidder SAJ; Miller DT; Furtmüller GJ; Ahmadi AR; Nägele F; Lopez J; Quan A; Budihardjo J; Lough DM; Akpinarli B; Etra JW; Vasilic D; Raimondi G; Lee WPA; Montgomery RA; Sun Z; Brandacher G
    Transplantation; 2018 Apr; 102(4):593-600. PubMed ID: 29298238
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acceptable Donor-Specific Antibody Levels Before and After Desensitization Therapy in Living Donor Kidney Transplantation.
    In JW; Nam M; Rho EY; Shin S; Hong YJ; Park KU; Song EY
    Clin Lab; 2020 Jan; 66(1):. PubMed ID: 32013363
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Deceased donor kidney transplantation across donor-specific antibody barriers: predictors of antibody-mediated rejection.
    Schwaiger E; Eskandary F; Kozakowski N; Bond G; Kikić Ž; Yoo D; Rasoul-Rockenschaub S; Oberbauer R; Böhmig GA
    Nephrol Dial Transplant; 2016 Aug; 31(8):1342-51. PubMed ID: 27190362
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pre-transplant HLA Antibodies and Delayed Graft Function in the Current Era of Kidney Transplantation.
    Morath C; Döhler B; Kälble F; Pego da Silva L; Echterdiek F; Schwenger V; Živčić-Ćosić S; Katalinić N; Kuypers D; Benöhr P; Haubitz M; Ziemann M; Nitschke M; Emmerich F; Pisarski P; Karakizlis H; Weimer R; Ruhenstroth A; Scherer S; Tran TH; Mehrabi A; Zeier M; Süsal C
    Front Immunol; 2020; 11():1886. PubMed ID: 32983110
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of de novo HLA donor specific antibodies (HLA-DSA), HLA antibodies (HLA-Ab) and allograft rejection post blood transfusion in kidney transplant recipients.
    Jalalonmuhali M; Carroll RP; Tsiopelas E; Clayton P; Coates PT
    Hum Immunol; 2020 Jul; 81(7):323-329. PubMed ID: 32327243
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Outcome of Pretransplantation Therapeutic Plasma Exchange in Highly Sensitized Deceased-donor Kidney Transplant Recipients.
    Tipjaiaue P; Ingsathit A; Kantachuvesiri P; Rattanasiri S; Thammanichanond D; Mongkolsuk T; Arpornsujaritkun N; Sumethkul V; Kantachuvesiri S
    Transplant Proc; 2017; 49(6):1249-1255. PubMed ID: 28735989
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Desensitization and heart transplantation of a patient with high levels of donor-reactive anti-human leukocyte antigen antibodies.
    Bućin D; Gustafsson R; Ekmehag B; Kornhall B; Algotsson L; Lund U; Otto G; Koul B
    Transplantation; 2010 Dec; 90(11):1220-5. PubMed ID: 20885338
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and Efficacy of Alemtuzumab Induction in Highly Sensitized Pediatric Renal Transplant Recipients.
    Kim IK; Choi J; Vo AA; Kang A; Patel M; Toyoda M; Mirocha J; Kamil ES; Cohen JL; Louie S; Galera O; Jordan SC; Puliyanda DP
    Transplantation; 2017 Apr; 101(4):883-889. PubMed ID: 27495773
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcome of recipients of human leukocyte antigen incompatible kidney transplants who underwent desensitization at King Fahad Specialist Hospital, Dammam, Saudi Arabia.
    Idris MA; Hossain A; Muntasir MA; Marmi A; Aldajani AA; Aljamaan YM; Akhtar M; Housawi A
    Saudi J Kidney Dis Transpl; 2017; 28(3):499-506. PubMed ID: 28540885
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 32 Doses of Bortezomib for Desensitization Is Not Well Tolerated and Is Associated With Only Modest Reductions in Anti-HLA Antibody.
    Moreno Gonzales MA; Gandhi MJ; Schinstock CA; Moore NA; Smith BH; Braaten NY; Stegall MD
    Transplantation; 2017 Jun; 101(6):1222-1227. PubMed ID: 27379560
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Subclinical Antibody-mediated Rejection After Kidney Transplantation: Treatment Outcomes.
    Parajuli S; Joachim E; Alagusundaramoorthy S; Blazel J; Aziz F; Garg N; Muth B; Mohamed M; Mandelbrot D; Zhong W; Djamali A
    Transplantation; 2019 Aug; 103(8):1722-1729. PubMed ID: 30507740
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Desensitization in heart transplant recipients: Who, when, and how.
    Shah KS; Patel J
    Clin Transplant; 2019 Aug; 33(8):e13639. PubMed ID: 31206862
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.